Compare SLND & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLND | LITS |
|---|---|---|
| Founded | 1900 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.4M | 25.7M |
| IPO Year | 2021 | 2003 |
| Metric | SLND | LITS |
|---|---|---|
| Price | $0.67 | $0.94 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | ★ 574.3K | 113.6K |
| Earning Date | 05-11-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $772,168,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.59 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.51 | $0.69 |
| 52 Week High | $5.34 | $3.03 |
| Indicator | SLND | LITS |
|---|---|---|
| Relative Strength Index (RSI) | 49.82 | 50.86 |
| Support Level | $0.64 | $0.89 |
| Resistance Level | $0.75 | $0.99 |
| Average True Range (ATR) | 0.08 | 0.05 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 63.84 | 59.14 |
Southland Holdings Inc is an infrastructure construction company in North America. The company's infrastructure projects range from water conveyance systems and tunnels to long-span bridges and vertical structures. The company operates in two distinct segments: Civil and Transportation. The civil segment operates throughout North America and specializes in services that include the design and construction of water pipelines, pump stations, lift stations, water and wastewater treatment plants, concrete and structural steel, outfall, and tunneling. The transportation segment operates throughout North America and specializes in services that include the design and construction of bridges, roadways, marine, dredging, ship terminals and piers, and specialty structures and facilities.
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.